Sorry, you need to enable JavaScript to visit this website.

PAD POST VASCULAR INTERVENTION : Learning About XARELTO® | Xarelto® (rivaroxaban) Welcome Kit

Learning About XARELTO®


Beginning a new medication can feel like a big commitment. But with a few tips and ongoing support, it’s possible to get started—for yourself and for those who care about you. First things first, be sure to fill your XARELTO® prescription if you haven’t yet.

What is XARELTO®?

XARELTO® belongs to a group of medicines called direct oral anticoagulants, or DOACs for short. Like other DOACs, XARELTO® has few drug interactions, no known dietary restrictions, and you don’t need to have frequent blood tests to see if XARELTO® is working.

How does XARELTO® work with aspirin?

Both XARELTO® and aspirin help prevent serious blood clots from forming and growing—but they work in different ways:

  • XARELTO® works by slowing down the blood’s clotting process. It does this by selectively targeting just 1 critical factor needed for blood to clot—Factor Xa.
  • Aspirin is an antiplatelet blood thinner that works by helping to keep platelets (which are pieces of blood cells) from sticking together and forming blood clots.

XARELTO® for People With PAD

XARELTO®, when taken with low-dose aspirin, helps reduce the risk of a sudden decrease in blood flow to the legs, major amputation, serious heart problems, or stroke in people with PAD, including people who have recently had a vascular intervention (a procedure to improve blood flow to the legs).

almost85%Did not have
a major blood-clotting
event after vascular intervention*

Significantly reduces hospitalizations and additional procedures after vascular intervention.

In a clinical study, almost 85% of people who took XARELTO®, in combination with low-dose aspirin, did not have a heart attack, stroke, sudden decrease in blood flow in the legs, or amputation after vascular intervention. XARELTO® is also proven to significantly reduce the need for additional vascular procedures or hospitalization due to blood-flow issues in the legs.

*The rate of a first event like a stroke, heart attack, poor blood flow in the legs, and amputation was 15.5% for people taking XARELTO® plus aspirin versus 17.8% for aspirin alone. Patients were followed for an average length of treatment of 30 months.

Remember, all blood thinners come with a risk of bleeding. Less than 2% of people taking XARELTO®, in combination with aspirin, experienced major bleeding versus 1% of people taking only low-dose aspirin.